Published Technical Disclosure Archive

Novel Therapeutic Applications of Cell-Penetrating Peptide-XIAP-BIR3 Conjugates

Publication ID: 24-11857609_0002_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Novel Therapeutic Applications of Cell-Penetrating Peptide-XIAP-BIR3 Conjugates,” Published Technical Disclosure No. 24-11857609_0002_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857609_0002_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,609.

Summary of the Inventive Concept

This inventive concept expands the scope of cell-penetrating peptide-XIAP-BIR3 conjugates to treat various neurological disorders, including chronic traumatic encephalopathy (CTE), Alzheimer's disease, Parkinson's disease, and glioblastoma.

Background and Problem Solved

The original patent focused on ocular delivery of cell-penetrating therapeutics for retinal edema treatment. However, the core technology has broader potential applications. This inventive concept addresses the need for effective treatments for neurological disorders, leveraging the XIAP-BIR3 conjugate's ability to inhibit apoptosis and promote cellular survival.

Detailed Description of the Inventive Concept

The new claims describe novel therapeutic applications of cell-penetrating peptide-XIAP-BIR3 conjugates. For instance, claim 1 proposes a system for treating CTE by administering the conjugate to the patient. Claim 2 outlines a method for preventing Alzheimer's disease by administering a prophylactic amount of the conjugate. Claim 3 describes a composition for treating Parkinson's disease using a sustained-release formulation. Claim 4 details a device for delivering the conjugate to the patient's brain using a micro-electromechanical systems (MEMS) device. Claim 5 proposes a method for treating glioblastoma by targeting the conjugate to glioblastoma cells using a glioblastoma-specific antibody.

Novelty and Inventive Step

The new claims introduce novel therapeutic applications of cell-penetrating peptide-XIAP-BIR3 conjugates, expanding the technology's scope beyond ocular delivery and retinal edema treatment. The inventive step lies in recognizing the conjugate's potential to address various neurological disorders, and developing new methods, systems, and compositions to achieve this.

Alternative Embodiments and Variations

Alternative embodiments may include using different cell-penetrating peptides, varying the XIAP-BIR3 conjugate's composition, or exploring other delivery methods, such as nanoparticles or viral vectors. Variations could also involve targeting specific cell types or tissues within the brain.

Potential Commercial Applications and Market

This inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of neurological disorders. The target market includes companies developing treatments for CTE, Alzheimer's disease, Parkinson's disease, and glioblastoma, as well as research institutions and hospitals.

CPC Classifications

SectionClassGroup
A A61 A61K38/55
A A61 A61K9/0048
A A61 A61K47/64
A A61 A61P27/02

Field of Art

Pharmaceutical biotechnology, specifically targeted drug delivery systems for neurological and ocular therapeutics, involving cell-penetrating peptides and protein conjugation techniques

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in biotechnology or pharmaceutical sciences, experienced in protein engineering, drug delivery mechanisms, and peptide conjugation strategies, familiar with techniques for crossing biological barriers

Obviousness Rationale

The PTD represents a predictable extension of the source patent's core technology by applying the established cell-penetrating peptide-XIAP-BIR3 conjugate to additional neurological disorders. A PHOSITA would recognize the fundamental mechanism of cell penetration and targeted protein delivery is transferable across different disease contexts. The technical approach of using cell-penetrating peptides to deliver therapeutic proteins is well-established and would suggest similar strategies could be applied to other neurological conditions.

Obvious Combinations & Variations

Source Patent Element
Cell-penetrating peptide (Penetratinl) conjugated with XIAP-BIR3 for ocular delivery
PTD Variation
Applying the same conjugate strategy to neurological disorders like CTE and Alzheimer's disease
Obviousness Reasoning
Known technique of repurposing drug delivery mechanisms across related therapeutic areas, with predictable results of cellular penetration and potential therapeutic effect
Source Patent Element
Eye drop formulation with specific concentration range of conjugate
PTD Variation
Developing sustained-release formulations for neurological drug delivery
Obviousness Reasoning
Predictable pharmaceutical engineering approach of modifying drug delivery mechanisms, representing a standard design choice for extending therapeutic applications
Source Patent Element
Targeting specific cellular mechanisms using XIAP-BIR3 conjugate
PTD Variation
Using targeted antibody conjugation for glioblastoma-specific delivery
Obviousness Reasoning
Known technique of enhancing drug targeting through molecular conjugation, representing a finite set of predictable modification strategies
Source Patent Element
Use of cell-penetrating peptides to enhance cellular uptake
PTD Variation
Exploring alternative delivery methods like MEMS devices and nanoparticles
Obviousness Reasoning
Obvious extension of existing drug delivery technologies, representing standard engineering approaches to improving therapeutic administration
Source Patent Element
Therapeutic approach of inhibiting apoptosis in specific cellular contexts
PTD Variation
Expanding therapeutic targets to multiple neurological disorders
Obviousness Reasoning
Predictable scientific approach of investigating similar molecular mechanisms across related disease states, representing a logical progression of research
35 U.S.C. § 103 Summary: Based on US Patent 11857609's disclosure of cell-penetrating peptide-XIAP-BIR3 conjugates for ocular delivery, the present publication demonstrates that a Person Having Ordinary Skill In The Art would find the extension of this technology to neurological disorder treatments obvious, as the fundamental molecular mechanisms and delivery strategies represent predictable variations within the established technological framework.

Original Patent Information

Patent NumberUS 11,857,609
TitleOcular delivery of cell permeant therapeutics for the treatment of retinal edema
Assignee(s)The Trustees of Columbia University in the City of New York